Neurological complications of COVID-19: from pathophysiology to rehabilitation. An overview.

Main Article Content

Loredana Raciti
Rocco Salvatore Calabrò


COVID-19; neurocovid; pandemic; neurological complications.


Objective: To evaluate how the SARS-COV2 is able to affect the nervous system, the main neurological manifestation, and the treatment used, including neurorehabilitation.

Methods: Studies performed during the current year that fulfilled inclusion criteria were selected from PubMed, Scopus, Cochrane, and Web of Sciences databases. The search combined the terms "Covid 19," "rehabilitation/treatment," and "neurological complications."

Results: The exact route by which SARS-CoV-2 can penetrate the CNS is still unknown, although a possible retrograde transynaptic pathway from peripheral nerve endings, and/or through the olfactory bulb, have been suggested. An early management of COVID-19 by a multiprofessional team is fundamental to avoid long term sequaele. Rehabilitation is recommended to improve respiratory and cardiac function, as well as to avoid long term neurological complications.

Conclusions: As no specific conclusions in term of prognosis and treatment could be done, research and consensus paper are needed to provide NeuroCovid patients with the best treatment options, including neurorehabilitation.


Download data is not yet available.
Abstract 11 |


1. World Health Organization (WHO). Statement on the Second Meeting of the International Health Regulations Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV). WHO: Geneva, Switzerland, 2005; Available online:
2. World Health Organisation. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19–11; WHO: Geneva, Switzerland, 2020; Available online:; 11-March-2020
3.; accessed on August, 19, 2020.
4. Raciti L, Calabrò RS. Can volcanic trace elements facilitate Covid-19 diffusion? A hypothesis stemming from the Mount Etna area, Sicily. Med Hypotheses. 2020;144:110058. doi:10.1016/j.mehy.2020.110058
5. Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020, 94, 154–155.
6. Nishiura H, Jung SM, Linton C et al. The Extent of Transmission of Novel Coronavirus in Wuhan, China, 2020. J Clin Med. 2020, 9, 330.
7. Park M, Cook A, Lim JT, Sun Y, Dickens B. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. J Clin Med. 2020, 9, 967.
8. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; Mar 17.
9. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020, 92, 577–583.
10. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia ZY. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020, 35, 1545–1549.
11. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Nature 2003; 426: 450–454.
12. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020; 20: 124-7.
13. Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011; 85(9): 4122–4134
14. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280
15. Lei S, Jiang F Su W, Chen C, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 2020, 21, 100331.
16. Guan, WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020, 382, 1708–1720.
17. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China. JAMA Netw. Open 2020, 3, e205619
18. Wang, Z.; Chen, X.; Lu, Y.; Chen, F.; Zhang,W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020, 14, 64–68.
19. Kim ES, Chin BS, Kang CK, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus2 Infection: A Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. J Korean Med Sci. 2020, 35, e142.
20. Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020, 94, 154–155.
21. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020, 80, 656–665.
22. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020, 368, m1091.
23. WHO. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected. Available online: (accessed on 17 March 2020).
24. Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, Ge XY. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 2020, 22, 80–85.
25. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. J Clin Med. 2020, 9, 1225.
26. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17: 181-92
27. Desforges M, Le Coupanec A, Dubeau P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 2019; 12. pii: E14.
28. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 2008; 82: 7264-75
29. Arbour N, Cote G, Lachance C, Tardieu M, Cashman NR, Talbot PJ. Acute and persistent infection of human neural cell lines by human coronavirus OC43. J Virol 1999; 73: 3338-50.
30. Arbour N, Ekande S, Cote G, et al. Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. J Virol 1999; 73: 3326-7.
31. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol 2000; 4: 8913-21.
32. Brison E, Jacomy H, Desforges M, Talbot PJ. Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein. J Virol 2011; 85: 12464-73.
33. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020; 11: 995-8.
34. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
35. N. Karimi, N. Rouhani, COVID 19 and intra cerebral hemorrhage: causative or coincidental New Microb New Infect. [Internet] (2020) 100669.
36. Dubé M, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ. Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43, J Virol. 92 (17) (2018).
37. Nogués MA, Benarroch E. Respiratory control disorders and respiratory motor unit, Neurol Argent. 3 (3) (2011) 167–175.
38. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients, J Med Virol. 2 (2020) 0–2.
39. Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: Underestimated damage to nervous system Travel Med Infect Dis. 2020;101642. doi:10.1016/j.tmaid.2020.101642
40. Xu Z, Shi L, Wang Y, et al. Pathological fi ndings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; Feb 18. [Epub ahead of print].
41. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; Feb 28.
42. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol, 2020 doi:
43. Jin M, Tong Q. Rhabdomyolysis as potential late complication associated with 2019 novel coronavirus disease. Emerg Infect Dis 2020.
44. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020; 12:8
45. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus, 2020 12(3):e7352.
46. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis, 2020. doi:
47. Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. SSRN Electron J. 2020.
48. Connors J, Levy J. Thromboinflammation and hypercoagulability of COVID-19. J Thromb Haemost. 2020
49. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID- 19 and other coronaviruses. Brain Behav Immun 2020; doi:
50. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 2020;
51. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARSCoV-2 infection. N Engl J Med, 2020 doi:
52. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-4.
53. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci 2018; 12: 386.
54. Zhao H, Shen D, Zhou H , Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020;
55. Ottaviani D, Boso F, Tranquillini E, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol Sci. 2020;41(6):1351-1354.
56. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016; 387(10027):1531–1539.
57. Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T. Guillain-Barré Syndrome associated with SARS-CoV-2 infection. IDCases. 2020;20:e00771
58. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020;19(6):102537.
59. Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574-2576.
60. Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. Acta Neurol Scand. 2020;142(1):14-22.
61. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology 2020; doi: 10.1212/WNL.0000000000009619.
62. Ferrarese C, Silani V, Priori A, et al. An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID). Neurol Sci. 2020;41(6):1355-1359.
63. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020, 133, 1025–1031.
64. A Lake, M. What we know so far: COVID-19 current clinical knowledge and research. Clin Med. 2020, 20, 124–127.
65. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020, 80, 656–665.
66. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020.
67. Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol. 2020.
68. Zheng F, Tang W, Li H, et al Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur. Rev. Med Pharmacol Sci. 2020, 24, 3404–3410.
69. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected Coronavirus Disease 2019 in two emergency departments outside of Hubei, China J Med Virol. 2020.
70. Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020, 47, 1275–1280.
71. Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L. Radiology Perspective of Coronavirus Disease 2019 (COVID-19): Lessons From Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. Am J Roentgenol. 2020, 214, 1078–1082.
72. Deng, S.-Q.; Peng, H.-J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med. 2020, 9, 575.
73. Khan S, Siddique R, Shereen MA, et al. The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. J Clin Microbiol 2020;
74. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 2016; 531:381–5.
75. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020; 382:2327–36.
76. Badaya A, Sasidhar YU. Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations. Sci Rep. 2020; 10:5501. doi: 10.1038/s41598-020-62423-y
77. Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors. J Theoretical Biol. 2008; 254:861–7. doi: 10.1016/j.jtbi.2008.07.030
78. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30:269–71.
79. Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrobial Agents 2007; 30:297–308.
80. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infectious Dis. 2007; 7:549–58.
81. Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. (2003) 349:507–8.
82. Sosnowski K, Lin F, Mitchell ML, White H. Early rehabilitation in the intensive care unit: an integrative literature review. Aust Crit Care. 2015;28(4):216-225.
83. Curci C, Pisano F, Bonacci E, et al. Early rehabilitation in post-acute COVID-19 patients: data from an Italian COVID-19 rehabilitation unit and proposal of a treatment protocol. A cross-sectional study. Eur J Phys Rehabil Med. 2020; doi:10.23736/S1973-9087.20.06339-X.
84. Maresca G, De Cola MC, Caliri. S. et al. Moving towards novel multidisciplinary approaches for improving elderly quality of life: The emerging role of telemedicine in Sicily. J Tel Telecare, 2018; 1357633X17753057.
85. De Cola MC, De Luca R, Bramanti A, Bertè F, Bramanti P, Calabrò RS. Tele-health services for the elderly: a novel southern Italy family needs-oriented model. J Tel Telecare, 2016; 22(6). 356-362.
86. Pedretti. Monaldi Arch Chest Dis, 2018
87. Kemps HMC, Brouwers RWM, Cramer MJ, et al. Recommendations on how to provide cardiac rehabilitation services during the COVID-19 pandemic. Neth Heart J 2020.
88. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus. 2020;
89. Li Y-C, Bai W-Z, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;
90. Brugliera L, Spina A, Castellazzi P, et al. Nutritional management of COVID-19 patients in a rehabilitation unit. Eur J Clin Nutrit 2020; p. 1–4.,
91. Brugliera L, Spina A, Castellazzi P, et al. Rehabilitation of COVID-19 patients. J Rehabil Med 2020; 52: jrm00046;
92. Smith SR, Jenq G, Claflin T, Magnant C, Haig AJ, Hurvitz E. Proposed workflow for rehabilitation in a field hospital setting during the COVID-19 pandemic. PMR 2020.
93. Carda S, Invernizzi M, Bavikatte G, et al. The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view. Ann Phys Rehabil Med. 2020; doi:10.1016/
94. Li J. Rehabilitation management of patients with COVID- 19. Lessons learned from the first experiences in China. Eur J Phys Rehabil Med 2020. PMID: 32329589
95. Wainwright TW, Low M. Beyond acute care: why collaborative self-management should be an essential part of rehabilitation pathways for COVID-19 patients. J Rehabil Med 2020; 52: jrm00055
96. Iannaccone S, Alemanno F, Houdayer E, et al. COVID-19 rehabilitation units are twice as expensive as regular rehabilitation units. J Rehabil Med. 2020;52(6):jrm00073).
97. Simpson R, Robinson L. Rehabilitation after critical illness in people with COVID-19 infection. Am J Phys Med Rehabil 2020; 99: 470–474.
98. Kiekens C, Boldrini P, Andreoli A, et al. Rehabilitation and respiratory management in the acute and early post-acute phase. "Instant paper from the field" on rehabilitation answers to the Covid-19 emergency. Eur J Phys Rehabil Med. 2020; doi: 10.23736/S1973-9087.20.06305-4;
99. Levy J, Léotard A, Lawrence C, et al. A model for a ventilator-weaning and early rehabilitation unit to deal with post-ICU impairments with severe COVID-19. Ann Phys Rehabil Med. 2020. doi: 10.1016/;
100. Zhao HM, Xie YX, Wang C. Recommendations for respiratory rehabilitation in adults with COVID-19. Chin Med J (Engl). 2020. doi: 10.1097/CM9.0000000000000848).
101. Stam HJ, Stucki G, Bickenbach J. Covid-19 and Post Intensive Care Syndrome: A Call for Action. J Rehabil Med. 2020;52(4):jrm00044. doi: 10.2340/16501977-2677;
102. Wang YL, Zhu FZ, Zeng L, et al. Guideline for diagnosis and treatment of spine trauma in the epidemic of COVID-19 [published online ahead of print, 2020 Jun 17]. Chin J Traumatol. 2020;S1008-1275
103. Calabrò RS, Naro A, Russo M. et al. The role of virtual reality in improving motor performance as revealed by EEG: a randomized clinical trial. J Neuroeng Rehabil. 2017;14(1):53.
104. Bruni MF, Melegari C, De Cola MC, Bramanti A, Bramanti P, Calabrò RS. What does best evidence tell us about robotic gait rehabilitation in stroke patients: A systematic review and meta-analysis. J Clin Neurosci. 2018 Feb; 48: 11-17.
105. Maggio MG, Torrisi M, Buda A, et al. Effects of robotic neurorehabilitation through lokomat plus virtual reality on cognitive function in patients with traumatic brain injury: A retrospective case-control study. Int J Neurosci. 2019 doi: 10.1080/00207454.2019.1664519.
106. Portaro S, Russo M, Bramanti A, et al. The role of robotic gait training and tDCS in Friedrich ataxia rehabilitation: A case report. Medicine (Baltimore). 2019;98(8):e14447.
107. Straudi S, Benedetti MG, Venturini E, Manca M, Foti C, Basaglia N. Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial. NeuroRehabilitation. 2013;33(4):555-63.
108. Mehrholz J, Hädrich A, Platz T, Kugler J, Pohl M. Electromechanical and robot-assisted arm training for improving generic activities of daily living, arm function, and arm muscle strength after stroke. The Cochrane Library, 2012.

Most read articles by the same author(s)